Feb 5, 2019
Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease.
Ion channels are the molecular targets of many kinds of therapeutics, from cardiovascular disorders such as angina and arrhythmias, to metabolic disorders such as Type II diabetes, to neurological disorders including pain and stroke.
Ion channels remain an undeniably valuable type of drug-discovery target. However in the past 10-15 years, researchers’ attempts to expand the number of validated ion-channel drug targets and create new drugs against these have, for the most part, fallen flat.
Original article by Dr Douglas Krafte and Deborah Erickson
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: